Médecins Du Monde Et Al competitive analysis

Explore patent oppositions filed by Médecins Du Monde Et Al against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
Use Of Chimeric Antigen Receptor-Modified T Cells To Treat CancerTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAJul 2, 2019
Modified Fluorinated Nucleoside AnaloguesGILEAD PHARMASSETMar 27, 2017

Latest PTAB cases involving Médecins Du Monde Et Al

Discover the latest PTAB cases involving Médecins Du Monde Et Al, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Médecins Du Monde Et Al with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MÉDECINS DU MONDE ET AL2 - - -
GILEAD PHARMASSET - 16 - 10
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA - 51 - 7